ANNOUNCEMENT

NOBEL PRIZE 2026

This year's laureates, their fields, and the discoveries that earned them the prize.Live nowSee the winners
Moonbase
← Back to Awards
NIHNATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES

Achieving Xenograft Tolerance through Mixed Chimerism

Active
Institution
COLUMBIA UNIVERSITY HEALTH SCIENCES, NY
Principal investigator
Megan Sykes
Funding
$526K
Duration
2000–2026
Open portfolio

Moonbase score

Still being scored

Abstract

Project 2 Summary Project 2 is directed toward the induction of xenotransplantation tolerance through mixed hematopoietic chimerism, which is the only treatment regimen to date that has been successful in translating allogeneic tolerance induction from animal models to the clinic. In previous funding periods, we have overcome two of the major barriers to establishment of pig-to-primate mixed chimerism through: 1) development of α1,3-galactosyltransferase null (GalT- KO) miniature swine, which avoid the problem of hyperacute rejection due to natural anti-Gal antibodies; 2) addition of the hCD47 transgene to these GalT-KO swine, thereby avoiding removal of bone marrow stem cells due to phagocytosis by macrophages bearing the species-specific SIRP-alpha receptor; and 3) development of a methodology for intra-bone administration of porcine HSC (IBBM), which increased the ability of GalT-KO/CD47 inocula to engraft. These efforts have led to markedly increased levels and duration of porcine chimerism in baboons, as well as to prolonged survival of donor swine skin xenografts, in the absence of immunosuppression. In addition, we have demonstrated that mixed chimerism can lower the levels of natural anti-pig non-Gal antibodies and that this effect is proportional to the duration of chimerism. Since renal xenograft survival remains markedly affected by the levels of recipient anti-pig nAbs and since humans, like baboons, show marked variability in levels of such nAbs, ways of improving the levels and prolonging the duration of mixed chimerism will be required in order to make xenografts available to all potential human recipients. Our Specific Aims are now directed toward optimizing the effect of mixed chimerism on elimination of nAbs and inducing tolerance by: 1) Testing our new human cytokine receptor transgenic GalT-KO miniature swine as HSC donors; 2) Utilizing recipient Tregs to enhance xenogeneic chimerism; and 3) Applying our optimized mixed chimerism approach to induction of renal xenograft tolerance.

LOADING MOONBASE SCORE

NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESP01ZAI1-LAR-Xmixedswinetolerancexenografthscporcinechimerismminiature

Questions for COLUMBIA UNIVERSITY HEALTH SCIENCES

Answered by the team behind this research.

Same researchers, same institution, same topic, scored first.